Skip to main content


April 09, 2021
IO Learning invited Allison S. Aguado, MD, to discuss her 2021 Society of Interventional Radiology (SIR) presentation on the efficacy of minimally invasive interventional radiology treatments in pediatric cancer patients.
December 22, 2020
IO Learning spoke with Dr David Lacey, who was one of the first interventionists in the United States to utilize the Siemens Angio-CT, and was instrumental in the development of the current generation, Nexaris.
November 06, 2020
IO Learning spoke with Riccardo Lencioni, MD, FSIR, EBIR, regarding the trial design for the EMERALD-1 study, which was recently presented at CIO 2020 and was designated as a “CIO Best Poster.”
November 06, 2020
There is increasing evidence to support the concept of ablative-intent radioembolization, but the literature remains sparse for solitary HCC. We spoke with S. Ali Montazeri, MD, MPH, who presented his research on this topic at CIO 2020.
September 24, 2020
IO Learning invited Dr Nishita Kothary to discuss her 2020 SIR abstract, “Comparison of Drug-Eluting Beads versus Conventional Transarterial Chemoembolization: A Cost-Effectiveness Analysis.”
September 18, 2020
Dr Fabian Laage Gaupp, co-founder of the Tanzanian IR Initiative, discusses the current status of the program, as well as challenges faced during the COVID pandemic.
July 13, 2020
IO Learning invited Bela Kis, MD, PhD, to discuss his 2020 SIR Abstract of the Year, “Transarterial Chemoperfusion Treatment of Unresectable Pleural Mesothelioma: Interim Results of a Phase 2 Prospective Study.”
June 09, 2020
Dr Ripal Gandhi discusses his 2020 SIR abstract, “Overcoming Limitations in the Treatment of Locally Advanced Pancreatic Cancer With Transarterial Microperfusion Utilizing a Novel Dual-Balloon Catheter."
April 18, 2020
Dr Busch spoke with IO Learning about integrating the recently FDA-approved TULSA treatment into his practice.
March 25, 2020
Dr Bryce spoke with IO Learning about current breast cancer treatments and future options for the 1 in 8 women who will ultimately face breast cancer in their lifetime.
March 09, 2020
Dr Philip Low of On Target Laboratories discusses OTL38, a novel, tumor-targeted dye used to guide cancer surgery.
Back to Top